Suresh K. Durgam - Mar 1, 2025 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role: EVP, Chief Medical Officer
Signature: /s/ John P. Condon, Attorney-in-fact
Stock symbol: ITCI
Transactions as of: Mar 1, 2025
Transactions value $: -$475,494
Form type: 4
Date filed: 3/4/2025, 06:01 PM
Previous filing: Feb 4, 2025
Next filing: Mar 10, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITCI	Common Stock	Options Exercise		+8.74K	+33.51%		34.8K	Mar 1, 2025	Direct	F1
transaction	ITCI	Common Stock	Tax liability	-$475K	-3.71K	-10.65%	$128.20	31.1K	Mar 1, 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITCI	Restricted Stock Units	Options Exercise	$0	-8.74K	-33.33%	$0.00	17.5K	Mar 1, 2025	Common Stock	8.74K		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person.
F3	Each restricted stock unit represents a contingent right to receive one share of common stock.
F4	On March 1, 2024, the reporting person was granted 26,227 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.